Skip to main content
. 2022 Aug 10;25(3):557–565. doi: 10.1093/neuonc/noac195

Table 4.

Combined results of phase 1/2 serious adverse events, deemed related to study treatment

Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Noninfectious meningitis/arachnoiditis 1 1
Hydrocephalus 1
Nausea 1
Headache 2
Vomiting 1
Back pain 1
Extremity pain 1